Economic evaluation of cancer treatment strategies

European Journal of Cancer Part A

Volumn 33, Issue SUPPL. 4, 1997, Pages

  Torfs, K ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

Clinical trial; Cost; Cost effectiveness; Economics; Efficacy; Health economics; Outcomes; Quality of life

Indexed keywords

CANCER SURVIVAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0030751849     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00145-7     Document Type: Conference Paper

References (14)

1. Kaplan RM. Utility assessment for estimating quality-adjusted life years. In FA Sloan, ed., Valuing Health Care. Cambridge, Cambridge University Press, 1995, 15-30.
2. Bennett KJ, Torrance GW. Measuring health state preferences and utilities: rating scale, time trade-off and standard gamble techniques. In Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, Lippincott-Raven, 1996, 253-266.
3. Williams C, Coyle D, Gray A, et al. European School of Oncology Advisory Report to the Commission of the European Communities for the Europe Against Cancer programme cost-effectiveness in cancer care. Eur J Cancer 1995, 31A, 1410-1424.
4. Division of Drug Marketing, Advertising and Communications, U.S. Food and Drug Administration. Principles for the Review of Pharmacoeconomic Promotion. Draft version. Presented at Drug Information Association annual meeting, Orlando, Florida, 1995.
5. Van Hout BA, My AL, Gordon GS, Rutten FFH. Costs, effects and C/E ratios alongside a clinical trial. Health Econ 1994, 3, 309-319.
6. Weinstein MC. From cost-effectiveness ratios to resource allocation: where to draw the line? In Sloan FA, ed. Valuing Health Care. Cambridge, Cambridge University Press, 1995, 77-98.
7. Drummond MF, Stoddard GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford, Oxford University Press, 1989.
8. Commonwealth Department of Health, Housing, and Community Services. Guidelines for the Pharmaceutical Industry Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra, Australian Government Publishing Service, 1992.
9. Canadian Coordinating Office for Health Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals. Ottawa, Canadian Coordinating Office for Health Technology Assessment, 1994.
10. Ministry of Health of Ontario. Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Toronto, Ministry of Health, 1994.
11. Clemens K, Townsend R, Luscombe F, et al. Methodological and conduct principles for pharmacoeconomic research (PhRMA Pharmacoeconomics Guidelines). PharmacoEconomics 1995, 8, 169-174.
12. Task Force on Principles for Economic Analysis of Health Care Technology. Economic Analysis of Health Care Technology: a report on principles. Position paper. Ann Intern Med 1995, 122, 61-70.
13. Drummond MF, Jefferson TO, and the BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. Br Med J 1996, 313, 275-283.
14. Gold R, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York, Oxford University Press, 1996.